New prostate cancer screening approach boils down to 1.5
Feb. 21, 2017
Based on years of research and treating patients, E. David Crawford, MD, of Precision Prostate Cancer Care, has devised simple advice for men: if your prostate-specific antigen (PSA) is below 1.5, come back in five years for another test. If your PSA score is above 1.5, get more information.
In a study published in the journal Urology in 2016, Crawford and colleagues looked at data on 21,502 men aged 40 and older from Henry Ford Health System in Michigan.
They found prostate cancer rates to be 15 times higher among men with a PSA of 1.5 ng/mL or higher. Other studies have shown that 70 percent of men have PSAs below 1.5 ng/mL, and that half of all prostate cancer deaths were among men who had a PSA of 1.6 ng/mL or greater before age 50.
“I wanted to know: is there a PSA cutoff that shows a danger zone? We found out that 1.5 is a cutoff for goodness or badness,” says Crawford, who also serves as University of Colorado School of Medicine’s chief of Urologic Oncology. Read more about Crawford and his landmark research at UCHealth Today.
CU technology sheds light on prostate cancer
“Unbelievable” tumor-detection results
Nov. 11, 2015
For more than 20 years, University of Colorado School of Medicine experts led by E. David Crawford, MD, have been applying new technologies to help diagnose and treat prostate cancer. The goal is to send men home after a biopsy with a good idea of whether or not they have prostate cancer and how pervasive it might be – rather than waiting days for biopsy results. Now, they are pioneering development of a system that uses a type of light known as fluorescence spectroscopy to detect tumors quickly. And because the approach requires, on average, far fewer biopsy samples (called “cores”), patients should suffer less discomfort with lower risk of infection and bleeding as a result of the procedure. Read more.
Targeted focal therapy for early-stage prostate cancer
Minimally invasive technique may effectively control cancer without compromising quality of life
2011 Annual Report on Prostate Diseases, Harvard Health Publications
Treatment for prostate cancer ranges from active surveillance for early-stage cancer to radiation and radical prostatectomy for later-stage and aggressive cancers. Targeted focal cryotherapy treatment for prostate cancer, which uses minimally invasive techniques, could be a viable, middle-of-the-road solution, as outlined in this interview with Dr. David Crawford. Read more.